» It is evident that on the one hand, the immune system is vital for human health but that when dysregulated also has the capacity to kill the host. «
We now know that alongside other mechanisms of self-tolerance functionally specialized regulatory T cells (Treg) play a non-redundant role in controlling the immune response to both self-and environmental antigens. In this perspective, I describe my early work that contributed to the discovery of Treg and our more recent focus on elucidation of their function in intestinal homeostasis.
Do not mention the S word
After a brief spell in the City of London as an accountant, I was lucky enough to land a PhD position in Don Masons' Lab in the Cellular Immunology Unit, Sir William Dunn School of Pathology, University of Oxford. The CIU was headed by the dynamic and brilliant Alan Williams who, with Neil Barclay, discovered the Ig superfamily of leukocyte surface proteins. The Oxford group had produced a large series of monoclonal antibodies (mAbs) against cell surface proteins. These tools revolutionized the study of immune cells allowing the molecular characterization of cell surface proteins, as well as the description of markers that could distinguish functional immune subsets. With a mAb termed OX-22 (which recognized an isoform of CD45) in hand, I was able to build on work ongoing in Don's Lab to show that this antibody subdivided rat CD4
þ T cells into functionally distinct populations. The most striking observation was that transfer of the OX-22 high subset to nude rats led to a fatal inflammatory disease, which could be prevented by co-transfer of the reciprocal OX-22 low population (Powrie & Mason, 1990 Maloy & Powrie, 2001) .
The late eighties and early nineties was an exciting era in immunology with rapid advances in our understanding of the molecular basis of T-cell reactivity, thymic selection and cell intrinsic mechanisms of tolerance. The emphasis was on immune cell activation and interest in the concept of T-cell-mediated suppression, first postulated in the early 1970s, had declined as a result of poorly characterized mechanisms of action. Against this backdrop the re-emergence of dominant tolerance and immune suppression was treated with some scepticism. However, a small group of us pursued these studies and with advances in the area of CD4 þ T-cell heterogeneity based on cytokine secretion, this led to the renaissance of the immune suppression field. Suppressor cells were reborn as Treg, a term which more accurately describes their function.
Cytokines, intercellular messengers of the immune response Although not the primary aim of my project, Bob encouraged me to pursue these findings. Our results revealed a pathogenic role for Th1 cells and the cytokines interferon gamma (IFN-g) and tumour-necrosis factor (TNF)-a in driving experimental colitis (Powrie et al, 1994) . Similar to the rat studies, T-cell transfer colitis could be inhibited by CD4 þ CD45RB low T cells. As Th2 cells had been shown to reciprocally regulate the Th1 response, it seemed likely that differential activation of Th2 responses might explain Treg activity. However, we found that Treg function was IL-4-inde-pendent but required TGF-b production (Powrie et al, 1996) . These results together with those from Howard Weiner's Lab suggested that TGF-b producing Treg were functionally distinct from Th2 cells (Maloy & Powrie, 2001) . By the late nineties, interest in Treg cells and their fundamental role in immune homeostasis was increasing. The identification by Shimon Sakaguchi of CD25 as marker aided purification of these cells (Sakaguchi, 2005) . However, there was much debate about their mechanism of action with evidence for cytokine-dependent and -independent functions. The identification of the transcription factor forkhead box P3 (Foxp3) 
The importance of balance
The T-cell transfer model of colitis together with a number of genetic models of chronic intestinal inflammation, illustrated the importance of balance between inflammatory and regulatory pathways for intestinal health. These models showed us how genetic predisposition can render the host susceptible to the development of a deranged inflammatory response to our usually beneficial intestinal bacteria. Our results have shown that Foxp3þ Treg cells are abundant in the intestine and produce high levels of the immune suppressive cytokine interleukin 10 (IL-10), which is required for the control of intestinal homeostasis (Asseman et al, 1999) . We also found that the intestine is a specific site for the generation of Treg cells reactive with intestinal antigens through the actions of specialized dendritic cells, the vitamin A metabolite retinoic acid and TGF-b (Coombes and Powrie, 2008) . Similar results were obtained by Howard Weiner, Juan Lafaille and Jasmine Belkaid and provided a cellular basis for the welldescribed phenomenon of oral tolerance. Indeed the capacity of the intestinal immune system to favour Treg induction and production of IL-10 may be an important component of host commensal mutualism, preventing deleterious inflammatory responses to intestinal bacteria.
Deficiencies in regulatory pathways in the presence of triggering intestinal bacteria can lead to chronic intestinal inflammation. Initially thought to be driven by an interleukin 12 (IL-12)-dependent Th1 response, Kevin Maloy and I made the unanticipated observation in collaboration with Dan Cua and colleagues at DNAX, of a functional role for the IL-12 family cytokine, interleukin 23 (IL-23), as key driver of T-cell transfer colitis (Ahern et al, 2008) . Further analysis of this pathway led to the identification of a novel population of innate lymphoid cells (ILC) that mediate colitis through the production of Type-17 associated cytokines. Like Th17 cells, IL-23-driven ILC are dependent on the transcription factor retinoic acid receptor related orphan receptor gamma t (RORgt) indicating striking functional parallels between innate and adaptive lymphoid populations in the gut (Buonocore et al, 2010) . Together these results highlight the multiple activities of IL-23 that mediate tissue inflammatory responses (Fig 1) While we have made progress in identifying immune pathways that contribute to intestinal health and disease, we are only just beginning to unravel how these interface with the hundreds of species of commensal bacteria that inhabit the gastrointestinal tract. In IBD, genetically controlled malfunctions in a number of different pathways including intestinal barrier function, host defence and innate and adaptive inflammatory pathways, predispose to a dysregulated interplay between the microbiota and the intestinal immune system. The complex clinical and genetic subtypes in IBD, taken together with the individuality of the intestinal microbiota, raise formidable challenges ahead as we try to apply findings from experimental models to the development of novel therapies for IBD. Further understanding of individuality and commonality in IBD aetiology and pathogenesis is required to identify subgroups of patients that may benefit from more tailored therapeutic approaches. Towards this goal, in 2009 I was appointed as the Sidney Truelove Professor of Gastroenterology at Oxford to translate findings from fundamental mucosal immunology to the study of IBD. Advances in molecular microbiology, genetics and analysis of human clinical samples offer great hope that we can apply our growing knowledge of immune system bacterial interactions towards enhanced therapies for these devastating clinical conditions.
